Protective effect of intravitreal bevacizumab and sub-tenon triamcinolone acetonide against occlusion of choriocapillaris induced by photodynamic therapy

Ophthalmologica

Volumn 224, Issue 5, 2010, Pages 267-273

  Mukai, Ryo ^a,b   Kishi, Shoji ^a   Sato, Taku ^a   Watanabe, Goro ^a   Matsumoto, Hidetaka ^a  

^a GUNMA UNIVERSITY   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

Choriocapillaris occlusion; Hypofluorescence; Intravitreal bevacizumab; Photodynamic therapy; Triamcinolone acetonide

Indexed keywords

BEVACIZUMAB; INDOCYANINE GREEN; TRIAMCINOLONE ACETONIDE; ANGIOGENESIS INHIBITOR; COLORING AGENT; GLUCOCORTICOID; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CHORIOCAPILLARIS OCCLUSION; CHOROID DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; DENSITOMETRY; DISEASE SEVERITY; FEMALE; FLUORESCENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; RECURRENCE RISK; ANTAGONISTS AND INHIBITORS; ARTERIAL OCCLUSIVE DISEASES; CHOROID; CHOROID DISEASES; DIAGNOSTIC USE; DRUG COMBINATION; FASCIA; FLUORESCENCE ANGIOGRAPHY; INJECTION; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PHOTOCHEMOTHERAPY; PROSPECTIVE STUDY; VASCULARIZATION; VERY ELDERLY; VITREOUS BODY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ARTERIAL OCCLUSIVE DISEASES; CHOROID; CHOROID DISEASES; COLORING AGENTS; DRUG THERAPY, COMBINATION; FASCIA; FEMALE; FLUORESCEIN ANGIOGRAPHY; GLUCOCORTICOIDS; HUMANS; INDOCYANINE GREEN; INJECTIONS; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PHOTOCHEMOTHERAPY; PROSPECTIVE STUDIES; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 77955606301     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000287348     Document Type: Article

References (42)

1. Photodynamic therapy with verteporfin for age related-macular degeneration. Ophthalmology 2000; 107: 2314-2317.
2. Spaide RF, Sorenson J, Maranan L: Combined photodynamic therapy with vertepor-fin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003; 110 : 1517-1525.
3. Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA, Tewari A: Combined photody-namic therapy with verteporfin and intravit-real bevacizumab for choroidal neovascular-ization in age-related macular degeneration. Retina 2006; 26: 988-993.
4. Maruko I, Iida T, Saito M, Nagayama D, Saito K: Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 2007; 144 : 15-22.
5. GomiF, Sawa M, Sakaguchi H, Tsujikawa M, Oshima Y, Kamei M, Tano Y: Efficacy of in-travitreal bevacizumab for polypoidal cho-roidal vasculopathy. Br J Ophthalmol 2008; 92: 70-73.
6. Heiduschka P, Julien S, Hofmeister S, Bartz-Schmidt KU, Schraermeyer U: Bevacizumab (Avastin) does not harm retinal function after intravitreal injection as shown by electro-retinography in adult mice. Retina 2008; 28: 46-55.
7. Husain D, Kramer M, Kenny AG, Michaud N, Flotte TJ, Gragoudas ES, Miller JW: Effects of photodynamic therapy using verte-porfin on experimental choroidal neovascu-larization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthal-mol Vis Sci 1999; 40: 2322-2331.
8. Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H: Photodynamic effects on choroidal neovascularization and physiological cho-roid. Invest Ophthalmol Vis Sci 2002; 43: 830-841. (Pubitemid 34184504)
9. Otani A, Sasahara M, Yodoi Y, Aikawa H, Tamura H, Tsujikawa A, Yoshimura N: Indo-cyanine green angiography: guided photo-dynamic therapy for polypoidal choroidal vasculopathy. Am J Opht halmol 2007; 144 : 7-14.
10. Freund KB, Klais CM, Eandi CM, Ober MD, Goldberg DE, Sorenson JA, Yannuzzi LA: Se-quenced combined intravitreal triamcino-lone and indocyanine green angiography-guided photodynamic therapy for retinal angiomatous proliferation. Arch Ophthal-mol 2006; 124: 487-489.
11. Yannuzzi LA, Flower RW, Slakter JS: Indo-cyanine Green Angiography. St Louis, Mos-by, 1997, pp 50-62.
12. Giovannini A, Mariotti C, Ripa E, Scassel-lati-Sforzolini B: Indocyanine green angio-graphic findings in serpiginous choroidopa-thy. Br J Ophthalmol 1996; 80:536-540. (Pubitemid 26188153)
13. Howe LJ, Woon H, Graham EM, Fitzke F, Bhandari A, Marshall J: Choroidal hypoper-fusion in acute posterior multifocal placoid pigment epitheliopathy: an indocyanine green angiography study. Ophthalmology 1995; 102:790-798.
14. Obana A, Kusumi M, Miki T: Indocyanine green angiographic aspects of multiple evanescent white dot syndrome. Retina 1996; 16: 97-104.
15. Schmidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte TJ, Birngruber R: Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 1994; 101: 1953-1961.
16. Michels S, Schmidt-Erfurth U: Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci 2003; 44: 2147-2154.
17. Kaplan MJ, Somers RG, Greenberg RH, Ack-ler J: Photodynamic therapy in the management of metastatic cutaneous adenocarcino-mas: case reports from phase 1/2 studies using tin ethyl etiopurpurin (SnET2). J Surg Oncol 1998; 67: 121-125.
18. Schmidt-Erfurth U, Laqua H, Schlötzer-Schrehard U, Viestenz A, Naumann GO: Histopathological changes following photo-dynamic therapy in human eyes. Arch Ophthalmol 2002; 120: 835-844.
19. Schmidt-Erfurth U, Schlötzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Nau-mann GO: Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003; 44: 4473-4480.
20. Holz ER, Linares L, Mieler WF, Weinberg DV: Exudative complications after photody-namic therapy. Arch Ophthalmol 2003; 121: 1649-1652.
21. Ishikawa K, Kondo M, Ito Y, Kikuchi M, Nishihara H, Piao CH, Sugita T, Terasaki H: Correlation between focal macular electro-retinograms and angiographic findings after photodynamic therapy. Invest Ophthalmol Vis Sci 2007; 48:2254-2259.
22. Jain RK: Normalization of tumor vascula-ture: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62.
23. Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt KU, Tübingen Beva-cizumab Study Group, Schraermeyer U: Ul-trastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007; 143 : 995-1002.
24. Kiss C, Michels S, Prager F, Weigert G, Geit-zenauer W, Schmidt-Erfurth U: Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizum-ab. Retina 2006; 26: 877-881.
25. Ishida S, Usui T, Yamashiro K, Kaji Y, Ama-no S, Ogura Y, Hida T, Oguchi Y, Ambati J, Miller JW, Gragoudas ES, Ng YS, D'Amore PA, Shima DT, Adamis AP: VEGF164-medi-ated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 2003; 198:483-489.
26. Miyamoto K, Khosrof S, Bursell SE, Mo-romizato Y, Aiello LP, Ogura Y, Adamis AP: Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol 2000; 156:1733-1739.
27. Bakri SJ, Cameron JD, McCannel CA, Pulido JS, Marler RJ: Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 2006; 142 : 162-164.
28. Luthra S, Narayanan R, Marques LE, Chwa M, Kim DW, Dong J, Seigel GM, Neekhra A, Gramajo AL, Brown DJ, Kenney MC, Kup-permann BD: Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and micro-vascular endothelial cells. Retina 2006; 26: 512-518.
29. Heidusch ka P, Fietz H, Hof meister S, Schult-heiss S, Mack AF, Peters S, Ziemssen F, Niggemann B, Julien S, Bartz-Schmidt KU, Schraermeyer U, Tübingen Bevacizumab Study Group: Penetration of bevacizumab through the retina after intraretinal injection in the monkey. Invest Ophthalmol Vis Sci 2007; 48:2814-2823.
30. Shimomura Y, Hirata A, Ishikawa S, Okina-mi S: Changes in choriocapillaris fenestra-tion of rat eyes after intravitreal bevacizum-ab injection. Graefes Arch Clin Exp Ophthalmol 2009; 247:1089-1094.
31. Ozdemir H, Karacorlu SA, Karacorlu M: Early optical coherence tomography changes after photodynamic therapy in patients with age-related macular degeneration. Am J Ophthalmol 2006; 141: 574-576. (Pubitemid 43265973)
32. Costa RA, Farah ME, Cardillo JA, Calucci D, Williams GA: Immediate indocyanine green angiography and optical coherence tomography evaluation after photodynamic therapy for subfoveal choroidal neovasculariza-tion. Retina 2003; 23:159-165.
33. Jonas JB: Intravitreal triamcinolone aceton-ide for treatment of intraocular oedematous and neovascular diseases. Acta Ophthalmol Scand 2005; 83: 6 45-6
34. Edelman JL, Lutz D, Castro MR: Corticoste-roids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res 2005; 80:249-258.
35. Matsuda S, Gomi F, Oshima Y, Tohyama M, Tano Y: Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress. Invest Ophthalmol Vis Sci 2005; 46: 1062-1068.
36. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M: Corticoste-roids inhibitthe expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998; 12: 309-315.
37. Jonas JB, Ihloff AK, Harder B, Kreissig I, Schlichtenbrede F, Libondi T, Spandau UH, Vossmerbaeumer U: Intravitreal bevaci-zumab versus triamcinolone acetonide for exudative age-related macular degeneration. Ophthalmic Res 2009; 41: 21-27.
38. Sacu S, Michels S, Prager F, Weigert G, Du-navoelgyi R, Geitzenauer W, Pruente C, Schmidt-Erfurth U: Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results. Eye 2009, E-pub ahead of print.
39. Schmidt-Erfurth U, Diddens H, Birngruber R, Hasan T: Photodynamic targeting of human retinoblastoma cells using covalent low-density lipoprotein conjugates. Br J Cancer 1997; 75: 54-61.
40. Schmidt-Erfurth U, Hasan T: Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000; 45: 195-214.
41. Holz FG, Pauleikhoff D, Spaide RF, Bird AC: Age-Related Macular Degeneration. New York, Springer, 2004, pp 144-148.
42. Iriyama A, Obata R, Inoue Y, Takahashi H, Tamaki Y, Yanagi Y: Effect of posterior jux-tascleral triamcinolone acetonide on the efficacy and choriocapillaris hypoperfusion of photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 2008; 246: 339-344